Current treatment options for neuroendocrine tumors

Drugs of Today

Volumn 47, Issue 10, 2011, Pages 773-786

  Hörsch, Dieter ^a   Grabowski, P ^a   Schneider, C P ^a   Petrovitch, A ^a   Hommann, M ^a   Kaemmerer, D ^a   Baum, R P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GALLIUM 68; GEMCITABINE; GLUCOSE TRANSPORTER 2; IRINOTECAN; NEUROPEPTIDE RECEPTOR; OCTREOTIDE; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; TAXANE DERIVATIVE; VASCULOTROPIN;

ABLATION THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CHEMOTHERAPY; CRYOTHERAPY; CYTOTOXICITY; DISEASE COURSE; HUMAN; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; REVIEW;

HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81255210754     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.10.1673555     Document Type: Review

References (88)

1. Rindi, G., Klimstra, D.S., Arnold, R., et al. Nomenclature and classification of neuroendocrine neoplasm of the digestive system. In: WHO Classification of Tumours of the Disgestive System, 4th Edition. F.T. Bosman et al. (Eds.). International Agency for Research on Cancer (IARC): Lyon 2010, 13-4.
2. Anlauf, M., Gerlach, P., Schott, M. et al. [Pathology of neuroendocrine neoplasms]. Chirurg 2011, 82(7): 567-73.
3. Volante, M., Righi, L., Berruti, A., Rindi, G., Papotti, M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch 2011, 458(4): 393-402.
4. Modlin, I.M., Moss, S.F., Gustafsson, B.I., Lawrence, B., Schimmack, S., Kidd, M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg 2011: Advance publication.
5. Starker, L.F., Carling, T. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol 2009, 21(1): 29-33.
6. Jann, H., Roll, S., Couvelard, A. et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011, 117(15): 3332-41.
7. Yao, J.C., Hassan, M., Phan, A. et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18): 3063-72.
8. Caldarella, A., Crocetti, E., Paci, E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res 2011, 17(3): 759-63.
9. Rinke, A., Muller, H.H., Schade-Brittinger, C. et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27(28): 4656-63.
10. Yao, J.C., Shah, M.H., Ito, T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6): 514-23.
11. Raymond, E., Dahan, L., Raoul, J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6): 501-13.
12. Raymond, E., Niccoli, P., Raoul, J. et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4008.
13. Turaga, K.K., Kvols, L.K. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011, 61(2): 113-32.
14. Hill, J.S., McPhee, J.T., McDade, T.P., Zhou, Z., Sullivan, M.E., Whalen, G.F., Tseng, J.F. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009, 115(4): 741-51.
15. Kaemmerer, D., Prasad, V., Daffner, W., Horsch, D., Kloppel, G., Hommann, M., Baum, R.P. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.World J Gastroenterol 2009, 15(46): 5867-70.
16. Kaemmerer, D., Peter, L., Lupp, A. et al. Molecular imaging with Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011, 38(9): 1659-68.
17. Baum, R.P., Prasad, V., Hommann, M., Horsch, D. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008, 170: 225-42.
18. Neo-adjuvant peptide receptor mediated radiotherapy with 177Lutetium in front of curative intended liver transplantation in patients with hepatic metastasis of neuroendocrine tumors (NEO-LEBE) (NCT01201096). ClinicalTrials.gov Web site, Accessed October 24, 2011.
19. Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179(68): 77-9.
20. Reichlin, S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987, 109(3): 320-6. (Pubitemid 17034039)
21. Yamada, Y., Post, S.R., Wang, K., Tager, H.S., Bell, G.I., Seino, S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992, 89(1): 251-5.
22. Modlin, I.M., Pavel, M., Kidd, M., Gustafsson, B.I. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010, 31(2): 169-88.
23. Kvols, L.K., Martin, J.K., Marsh, H.M., Moertel, C.G. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985, 313(19): 1229-30. (Pubitemid 16205347)
24. Kvols, L.K., Moertel, C.G., O'Connell, M.J., Schutt, A.J., Rubin, J., Hahn, R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986, 315(11): 663-6. (Pubitemid 16055931)
25. Schmid, H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 286(1-2): 69-74. (Pubitemid 351680237)
26. Kvols, L., Wiedenmann, B., Oberg, K. et al. Safety and efficacy of pasireotide (S0M230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 2-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 4082.
27. Davis, G.R., Camp, R.C., Raskin, P., Krejs, G.J. Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome. Gastroenterology 1980, 78(2): 346-9. (Pubitemid 10128406)
28. Arnold, R., Rinke, A., Klose, K.J. et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005, 3(8): 761-71. (Pubitemid 41116728)
29. Faiss, S., Pape, U.F., Bohmig, M. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21(14): 2689-96. (Pubitemid 46606312)
30. Yao, J.C., Ricci, S., Winkler, R.E., Jehl, V., Pavel, M.E. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4011.
31. Wolin, E.M., Fazio, N., Saletan, S., Winkler, R.E., Panneerselvam, A., Kvols, L. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4075.
32. Anthony, L.B., Peeters, M., Hainsworth, J.D. et al. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4078.
33. Study of lanreotide autogel in non-functioning entero-pancreatic endocrine tumours (CLARINET) (NCT00353496). ClinicalTrials.gov Web site, Accessed October 24, 2011.
34. Kwekkeboom, D.J., Kam, B.L., van Essen, M. et al. Somatostatin-receptor- based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010, 17(1): R53-73.
35. De Jong, M., Breeman, W.A., Bernard, H.F. et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999, 43(4): 356-66. (Pubitemid 30113564)
36. Kwekkeboom, D.J., de Herder, W.W., Kam, B.L. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26(13): 2124-30.
37. Bushnell, D.L., Jr., O'Dorisio, T.M., O'Dorisio, M.S. et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010, 28(10): 1652-9.
38. Imhof, A., Brunner, P., Marincek, N. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011, 29(17): 2416-23.
39. Valkema, R., Pauwels, S., Kvols, L.K. et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36(2): 147-56. (Pubitemid 43320450)
40. Wehrmann, C., Senftleben, S., Zachert, C., Muller, D., Baum, R.P. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTANOC. Cancer Biother Radiopharm 2007, 22(3): 406-16. (Pubitemid 47067899)
41. Rufini, V., Calcagni, M.L., Baum, R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 2006, 36(3): 228-47. (Pubitemid 43817847)
42. Merola, E., Capurso, G., Campana, D., Panzuto, F., Monarca, B., Tomassetti, P., Delle Fave, G. Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Dig Liver Dis 2010, 42(6): 457-8.
43. Rolleman, E.J., Melis, M., Valkema, R., Boerman, O.C., Krenning, E.P., de Jong, M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010, 37(5): 1018-31.
44. Hoersch, D., Prasad, V., Petrovitch, A., Baum, R.P. Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective: Report of 30 consecutive patients. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst e14634.
45. Seregni, E., Maccauro, M., Coliva, A. et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 2010, 54(1): 84-91.
46. Kennedy, A.S., Dezarn, W.A., McNeillie, P. et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008, 31(3): 271-9.
47. Kalinowski, M., Dressler, M., Konig, A. et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009, 79(3): 137-42.
48. Klimstra, D.S., Modlin, I.R., Coppola, D., Lloyd, R.V., Suster, S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39(6): 707-12.
49. Moertel, C.G., Kvols, L.K., O'Connell, M.J., Rubin, J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68(2): 227-32.
50. Mitry, E., Baudin, E., Ducreux, M. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999, 81(8): 1351-5.
51. Fjallskog, M.L., Granberg, D.P., Welin, S.L., Eriksson, C., Oberg, K.E., Janson, E.T., Eriksson, B.K. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92(5): 1101-7. (Pubitemid 32861657)
52. Hainsworth, J.D., Spigel, D.R., Litchy, S., Greco, F.A. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006, 24(22): 3548-54. (Pubitemid 46630525)
53. Kulke, M.H., Wu, B., Ryan, D.P. et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006, 51(6): 1033-8.
54. de Lima Lopes, G., Jr., Chiappori, A., Simon, G. et al. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer 2007, 109(7): 1413-9.
55. Bajetta, E., Catena, L., Procopio, G. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007, 59(5): 637-42. (Pubitemid 46295128)
56. Moertel, C.G., Hanley, J.A., Johnson, L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980, 303(21): 1189-94. (Pubitemid 11207582)
57. Moertel, C.G., Lefkopoulo, M., Lipsitz, S., Hahn, R.G., Klaassen, D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced isletcell carcinoma. N Engl J Med 1992, 326(8): 519-23.
58. Rivera, E., Ajani, J.A. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998, 21(1): 36-8. (Pubitemid 28092969)
59. Sun, W., Lipsitz, S., Catalano, P., Mailliard, J.A., Haller, D.G. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005, 23(22): 4897-904. (Pubitemid 46223995)
60. Pavel, M.E., Heuck, F., Plöckinger, U. et al. Prospective randomized trial: Biotherapy versus chemotherapy in malignant nonfunctional neuroendocrine tumors of the pancreas and bronchial tract (ENET-1). 2008 Gastrointest Cancers Symp (Jan 25-27, Orlando) 2008, Abst 202.
61. Ramanathan, R.K., Cnaan, A., Hahn, R.G., Carbone, P.P., Haller, D.G. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001, 12(8): 1139-43. (Pubitemid 32834496)
62. Kulke, M.H., Stuart, K., Enzinger, P.C. et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24(3): 401-6. (Pubitemid 46630459)
63. Strosberg, J.R., Fine, R.L., Choi, J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117(2): 268-75.
64. NET01: A randomised phase II study comparing capecitabine plus streptozocin with or without cisplatin chemotherapy as treatment for unresectable or metastatic neuroendocrine tumours. http://www.ukinets.org/ clinical/docs/NET1- Trial.pdf. Accessed October 25, 2011.
65. Capecitabine and temozolomide for neuroendocrine cancers (NCT00869050). ClinicalTrials.gov Web site, Accessed October 25, 2011.
66. Combination chemotherapy and bevacizumab in treating patients with advanced neuroendocrine tumors (NCT00227617). ClinicalTrials.gov Web site, Accessed October 25, 2011.
67. Basu, B., Sirohi, B., Corrie, P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 2010, 17(1): R75-90.
68. Yao, J.C., Phan, A., Hoff, P.M. et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26(8): 1316-23.
69. Yao, J.C., Phan, A.T., Fogleman, D. et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate- grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 4002.
70. Kulke, M.H., Lenz, H.J., Meropol, N.J. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26(20): 3403-10.
71. Zurita, A.J., Heymach, J., Khajavi, M. et al. Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4079.
72. Capdevila, J., Teule, A., Castellano, D.E. et al. PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst TPS171.
73. Karhoff, D., Sauer, S., Schrader, J., Arnold, R., Fendrich, V., Bartsch, D.K., Horsch, D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 2007, 85(1): 45-53. (Pubitemid 46550025)
74. Tannapfel, A., Vomschloss, S., Karhoff, D. et al. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005, 123(2): 256-60. (Pubitemid 40194088)
75. Hobday, T.J., Rubin, J., Holen, K. et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 4504.
76. Lankat-Buttgereit, B., Horsch, D., Barth, P., Arnold, R., Blocker, S., Goke, R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005, 71(3): 131-40. (Pubitemid 40910932)
77. Yao, J.C., Zhang, J.X., Rashid, A. et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007, 13(1): 234-40. (Pubitemid 46121874)
78. Zitzmann, K., De Toni, E.N., Brand, S. et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85(1): 54-60. (Pubitemid 46550026)
79. Faivre, S., Kroemer, G., Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5(8): 671-88. (Pubitemid 44151605)
80. Bjornsti, M.A., Houghton, P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(5): 335-48. (Pubitemid 38579480)
81. Missiaglia, E., Dalai, I., Barbi, S. et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28(2): 245-55.
82. Yao, J.C., Phan, A.T., Chang, D.Z. et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate- grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26(26): 4311-8.
83. Yao, J.C., Lombard-Bohas, C., Baudin, E. et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28(1): 69-76.
84. RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (NCT00688623). ClinicalTrials.gov, Accessed October 25, 2011.
85. De Vries, E., Anthony, L.B., Sideris, L. et al. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 10624.
86. Shah, M.H., Lombard-Bohas, C., Ito, T. et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progressionfree survival in the RADIANT-3 trial. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011, 29(Suppl. 1): Abst 4010.
87. Pommier, R.F., Wolin, E.M., Panneerselvam, A., Saletan, S., Winkler, R.E., Van Cutsem, E. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3.7, Chicago) 2011] 2011, 29(15, Suppl.): Abst 4103.
88. Heaphy, C.M., de Wilde, R.F., Jiao, Y. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333(6041): 425.